Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Gastrointestinal 1

Conditions

Colorectal Neoplasms 5Pancreatic Neoplasms 3Ovarian Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Uterine Neoplasms 2Uterine Cervical Neoplasms 2Urinary Bladder Neoplasms 2Stomach Neoplasms 2Prostatic Neoplasms 2Neoplasms 2Lung Neoplasms 2Head and Neck Neoplasms 2Thyroid Neoplasms 1Thoracic Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Skin Neoplasms 1Respiratory Tract Neoplasms 1Respiratory Tract Diseases 1Rectal Neoplasms 1Noonan Syndrome 1Neoplasms, Squamous Cell 1Neoplasms by Site 1Multiple Myeloma 1Melanoma 1Lymphoma 1Lung Diseases 1Hematologic Neoplasms 1Glioma 1Gastrointestinal Neoplasms 1Esophageal Squamous Cell Carcinoma 1

Interventions

Cisplatin 116Radiotherapy 84Paclitaxel 77Fluorouracil 62Carboplatin 41Drug Therapy 38pembrolizumab 33Irinotecan 33tislelizumab 27Docetaxel 26Neoadjuvant Therapy 24Oxaliplatin 23toripalimab 22sintilimab 19camrelizumab 19Radiation 19Esophagectomy 18Capecitabine 17130-nm albumin-bound paclitaxel 17Surgical Procedures, Operative 16Nivolumab 16Leucovorin 15Cetuximab 14TP protocol 12S 1 (combination) 12Radiotherapy, Intensity-Modulated 12Albumin-Bound Paclitaxel 12nimotuzumab 11apatinib 10Immune Checkpoint Inhibitors 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Esophageal Squamous Cell Carcinoma × osimertinib × Gastrointestinal × Clear all
NCT04868877 2026-02-19

Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination

Merus B.V.

Phase 1/2 Active not recruiting
194 enrolled
GastrointestinalHead & Neck

Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Head and Neck Neoplasms, Stomach Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡